GW Pharmaceuticals (GW Pharmaceuticals) Change In Receivables : $-22.3 Mil (TTM As of Mar. 2021)

View and export this data going back to 2013. Start your Free Trial

What is GW Pharmaceuticals Change In Receivables?

GW Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2021 was $-13.8 Mil. It means GW Pharmaceuticals's Accounts Receivable increased by $13.8 Mil from Dec. 2020 to Mar. 2021 .

GW Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2020 was $-22.1 Mil. It means GW Pharmaceuticals's Accounts Receivable increased by $22.1 Mil from Dec. 2019 to Dec. 2020 .

GW Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2021 was $84.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. GW Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2021 was 50.84.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. GW Pharmaceuticals's liquidation value for the three months ended in Mar. 2021 was $392.7 Mil.

GW Pharmaceuticals Change In Receivables Historical Data

The historical data trend for GW Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GW Pharmaceuticals Change In Receivables Chart

GW Pharmaceuticals Annual Data

Trend

Sep11

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Dec19

Dec20

Change In Receivables

Get a 7-Day Free Trial

-0.74

-0.28

-0.80

-44.62

-22.10

GW Pharmaceuticals Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Change In Receivables	Get a 7-Day Free Trial															-13.63	-18.16	0.14	9.55	-13.80

GW Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.3 Mil.

GW Pharmaceuticals (NAS:GWPH) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

GW Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	84.947	/	152.466	*	91
=	50.84

2. In Ben Graham's calculation of liquidation value, GW Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

GW Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2021 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	458.101	-	197.97	+	0.75 * 84.947	+	0.5 * 137.627
=	392.7

GW Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of GW Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

GW Pharmaceuticals (GW Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GW Pharmaceuticals PLC (NAS:GWPH) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sovereign House, Chivers Way, Vision Park, Histon, Cambridge, GBR, CB24 9BZ

Website

http://www.gwpharm.com

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

Executives

Douglas B. Snyder	officer: Chief Legal Officer	SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB249BZ
Volker Knappertz	officer: Chief Medical Officer	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Cabot Brown	director	SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Adam D. George	officer: Secretary	SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Guy Geoffrey W Dr	director, officer: Executive Chairman	ETHICAL HOLDINGS PLC CORPUS CHRISTI HOUSE 9 WEST STREET GODMANCHESTER CAMBRIDGESHIRE PE18 A1
Christopher J. Tovey	officer: Chief Operating Officer	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Justin D. Gover	director, officer: Chief Executive Officer	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
James Noble	director	C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Alicia Secor	director	33 HAYDEN AVE., LEXINGTON MA 02421
Darren S Cline	officer: U.S. Chief Commercial Officer	35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
William A. Waldegrave	director	SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ
Scott M. Giacobello	officer: Chief Financial Officer	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Julian S Gangolli	officer: President, North America	4955 BASELINE AVENUE, SANTA YNEZ CA 93460